Good MorningEquity markets moved lower on Friday to end an uncertain week on a down note. The market is wrestling with the true meaning of the latest inflation data, and the early analysis is not good. The pace of inflation is stabilizing at current levels if not accelerating, which means the FOMC has yet to accomplish its goal. In this light, it may not be if the FOMC causes a recession but when because it may have to in the fight against inflation.
This week will be another tough one for the market. The following PCE Price index report is due out on Friday and it may echo the news in the CPI data. In this scenario, the odds of another 50 basis point interest rate hike will rise and there is still another month of data to go before the next Fed meeting. The takeaway here is that inflation is still a problem, the FOMC is still raising interest rates and the outlook for S&P 500 earnings is still in decline. Not much of a catalyst for the market to rally on.
Featured: Elon Musk's Next Big AI Project Could Open This Month (Ad) 
|
Consumer Discretionary | |
Michael Burry, made famous by the 2015 movie "The Big Short" is a widely known investor whose main focus is - according to a quote by the book and movie - "... find value wherever it can be found."
Well, looks like our Burry has found value in China of all places despite current negative sentimen... Read the Full Story |
|
From Our Partners | | Jeff Brown, founder and CEO of Brownstone Research, says he has uncovered what he calls one of the biggest discoveries of his career tied to the ongoing AI boom.
Brown is pointing to a key date, October 20, and is highlighting five AI-related opportunities outside the traditional stock market that most investors have never heard of. | | Click here to see the full research before October 20 |
|
Consumer Discretionary | |
Do you want to know more about the WHR dividend, its history and what you might expect from the company over the next few years? In that case, we cover how to evaluate the Whirlpool dividend, how the yield may change over time and whether the distribution will grow.
The key takeaway from all thi... Read the Full Story |
|
Industrials | |
Deere & Co. (NYSE: DE) stock is up approximately 4% in early trading after the company’s fourth-quarter earnings report. The heavy equipment manufacturer beat on both the top and bottom lines. The report highlights Deere’s ability to pass along at least some of its higher prices to... Read the Full Story |
|
From Our Partners | | Jeff Brown, the former tech executive who picked Nvidia in 2016 before it surged as high as 37,800 percent, just got inside Elon Musk's new Cybercab, a vehicle with no steering wheel or pedals.
In 2018, the New York Post called Musk a total fraud. Brown's latest footage shows just how far that technology has come since then. | | Watch the Cybercab footage and judge Elon Musk's technology yourself |
|
Consumer Discretionary | |
DraftKings (NASDAQ: DKNG) Q4 report was everything the market could have hoped for and more. Adding new jurisdictions, deepening penetration and increasing monetization have given the company leverage and shortened the time until profitability. The news has the stock up more than 9.0% in premarket... Read the Full Story |
|
Consumer Discretionary | |
It took a while, but it’s looking like Tesla Inc’s (NASDAQ: TSLA) recent price cuts from last month are paying off, and the stock is loving it. Shares of the electric vehicle (EV) king are up 100% from where they started the year, and seemingly well on their way to undoing last year&rs... Read the Full Story |
|
From Our Partners | | Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracking a new Elon Musk project he calls the most epic AI initiative in history.
The plan could give Musk access to 50 times more computing power than the rest of the world combined, a development Brown says is drawing attention from executives at Amazon, Microsoft, and Google.
Brown compares the scale of this project to the SpaceX IPO, which minted thousands of millionaires overnight. | | Click here to see the full details on Musk's next big move |
|
Healthcare | |
A new study published in Science Translational Medicine could introduce a profitable opportunity for makers of seizure drug medications. The discovery has immense medical implications, of course, but it could lead to a windfall for investors, particularly those holding Abbott Laboratories (NYSE: A... Read the Full Story |
|
Energy | | Pipeline operators Enterprise Product Partners L.P. (NYSE: EPD), Energy Transfer L.P. (NYSE: ET) and MPLX L.P. (NYSE: MPLX) are among energy-industry master limited partnerships outperforming the broader market while also throwing off high dividend yields.
That makes some of these companies worthy... Read the Full Story |
|
Industrials | |
Generac Holdings, Inc. (NYSE: GNRC) stock is up 7% the day after it posted mixed fourth-quarter and full-year earnings on February 15. But the stock is down 4% from the post-earnings rally that briefly took shares above $140 per share.
The rally has to be a relief to shareholders who have had t... Read the Full Story |
|
Consumer Discretionary | |
O’Reilly Automotive Inc. (NASDAQ: ORLY) is in buy range after clearing a base with a buy point north of $856.57. Investors hit the accelerator on February 9 following the company’s better-than-expected fourth-quarter report.
The company cited strength in both the consumer DIY segment... Read the Full Story |
|
Consumer Discretionary | |
The travel industry has been one of the most challenging sectors to invest in for the past few years, as COVID-19 was such a gut shot to the industry. Travel volume went to near-zero virtually overnight, and it still hasn't fully recovered.
While the US Travel Association doesn’t see a full... Read the Full Story |
|
Monday's Early Bird Stock Of The Day Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California. | | View Today's Stock Pick |
|
